25Sep. 2017Israeli immunotherapy co Enlivex Therapeutics raising $10m
Most of the round has already been secured from Korea Investment Partners and Hadasit Bio.
19Sep. 2017Enlivex Therapeutics Announces Closing Of USD 8 Million Series B Round Led by Korea Investment Partners (KIP) & Hadasit Bio Holdingings Ltd. (HBL)
Jerusalem (September 19, 2017): Enlivex Therapeutics Ltd., a clinical stage immunotherapy company, announced today the closing of $8 million equity financing round at a valuation of approximately $50 Million pre-closing….
19Sep. 2017Immuron Highlights Recent Milestones in Quest to Effectively Treat Multiple Forms of Fatty Liver Diseases That Impact Millions
Company’s lead drug candidate IMM-124E is well-positioned to pioneer successful treatment for NASH and NAFLD, diseases for which there is no proven effective treatment.
1Jul. 2017Hadasit Newsletter July 2017
SPOTLIGHT ON: promising new technologies from Hadasit companies
19Jun. 2017Hadasit Bio-Holdings (HBL) and BioTime Complete Shares Swap Transaction in Cellcure Neurosciences
As part of the transaction, HBL, which owns 21% of Cellcure’s share capital, will sell its entire holdings to BioTime, Inc., In exchange, BioTime will pay $12.75 million in Biotime…